ArticleBreast cancer research and treatment2024

Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.

Julia Foldi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.